Core Insights - Aclarion, Inc. is conducting the pivotal CLARITY trial to evaluate the clinical and economic value of its Nociscan technology for chronic low back pain surgery [1][2] - Nociscan aims to become the gold standard in identifying sources of low back pain using MR Spectroscopy and AI [1][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful lumbar discs [3][6] Clinical Trial Details - The CLARITY trial is a randomized, multi-center study involving 300 patients scheduled for surgical treatment of discogenic low back pain [2][3] - The trial will compare surgical outcomes based on Nociscan results, with a primary endpoint of back pain change measured on a 100mm VAS scale at 12 months [2][3] Market Context - Approximately 266 million people globally suffer from degenerative spine disease and low back pain, highlighting the significance of Aclarion's Nociscan solution [3][6] - The trial is fully funded and led by Dr. Nicholas Theodore from Johns Hopkins, indicating strong institutional support [2][3]
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site